ArticleJournal of physiology and biochemistry2019
Involvement of miR-30b in kynurenine-mediated lysyl oxidase expression.
Article in Journal of physiology and biochemistry, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 9 citations in OpenAlex.
- Targeting the microbiota-miRNA-protease axis: A new therapeutic avenue in melanoma.The FEBS journal · 2026Review
- Deciphering Collagen Phenotype Dynamics Regulators: Insights from In-Silico Analysis.Journal of bioinformatics and systems biology : Open access · 2024Article
- PPARs and the Kynurenine Pathway in Melanoma-Potential Biological Interactions.International journal of molecular sciences · 2023Review
- MiR-30 Family: A Novel Avenue for Treating Bone and Joint Diseases?International journal of medical sciences · 2023Review
- The Regulation of Collagen Processing by miRNAs in Disease and Possible Implications for Bone Turnover.International journal of molecular sciences · 2021Review
- Roles of Lysyl Oxidase Family Members in the Tumor Microenvironment and Progression of Liver Cancer.International journal of molecular sciences · 2020Review
- Age-related increase of kynurenine enhances miR29b-1-5p to decrease both CXCL12 signaling and the epigenetic enzyme Hdac3 in bone marrow stromal cells.Bone reports · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Microenvironment components profoundly influence the propensity of cancer metastasis through regulating key molecules controlling metastasis. Lysyl oxidase (LOX) contributes to extracellular matrix (ECM) remodeling, and finally promoting bone metastasis in breast cancer. Kynurenine (Kyn), a microenvironment component, is capable of regulating the biological behaviors of cancer cells, such as promoting node metastasis in vivo. However, it is still unclear whether Kyn controls the generation of LOX. In the current study, a significant increase of migration in the Kyn (30, 50, 100, 200, and 500 μM) group was detected compared with that in the control group in 95D cells in vitro. Subsequently, we demonstrated that 50 μM Kyn not only substantially upregulated the mRNA and secreted levels of LOX rather than cytoplasmic LOX, but also markedly reduced the level of miR-30b at the same time. Furthermore, the direct interaction between LOX mRNA and miR-30b was also confirmed by dual-luciferase assay system. Most importantly, not only was Kyn-induced increase of LOX mRNA significantly attenuated on miR-30b mimics treatment, but also Kyn-mediated the upregulation of the mRNA, and secreted levels of LOX were distinctly strengthened on miR-30b inhibitor treatment. These results suggest that miR-30b is involved in Kyn-mediated LOX expression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.